海思科：创新药环泊酚注射液获得拓展儿童人群批准

Core Viewpoint - Company subsidiary Shenyang Haishike Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for the use of Ropivacaine injection in pediatric and adolescent general anesthesia induction and maintenance, marking a significant advancement in pediatric anesthesia options [1] Group 1: Product Approval - The approval includes a revised safety information in the product's instructions [1] - Ropivacaine is a new Class I intravenous anesthetic developed by the company, which has already been approved for multiple indications in China [1] Group 2: Clinical Value - The product offers a more comfortable and safer option for pediatric patients, demonstrating excellent clinical application value [1] Group 3: Regulatory Progress - The company has submitted a New Drug Application (NDA) for the product to the FDA, which is currently under review [1]